AbCellera Biologics (ABCL) Net Margin (2020 - 2026)
AbCellera Biologics (ABCL) reported Net Margin of 519.12% for Q1 2026, up 55812.0% on a YoY basis from N/an in Q1 2025, and down 2503.04% quarter-over-quarter from 19.94% in Q4 2025.
AbCellera Biologics (ABCL) Net Margin (2020 - 2026) Analysis & Trends
AbCellera Biologics has reported Net Margin for 7 years, with the latest figure at 519.12% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin rose 55812.0% year-over-year to 519.12%; the trailing twelve-month figure through Mar 2026 stood at 181.75% (up 54448.0% YoY), and the FY2025 full-year result was 194.88%, up 36995.0% from the prior year.
- Net Margin for Q1 2026 stood at 519.12%, down from 19.94% in the prior quarter.
- The five-year high for Net Margin was 53.25% in Q1 2022, with the low at 1077.24% in Q1 2025.
- Historically, Net Margin has averaged 381.55% across 5 years, with a median of 407.98% in 2024.
- The largest YoY upside for Net Margin was 65748 bps in 2025 against a maximum downside of 66926 bps in 2025.
- AbCellera Biologics' Net Margin stood at 138.75% in 2022, then plunged by 270 bps to 513.67% in 2023, then plunged by 32 bps to 677.43% in 2024, then surged by 97 bps to 19.94% in 2025, then tumbled by 2503 bps to 519.12% in 2026.
- The last three Net Margin figures came in at 519.12% (Q1 2026), 19.94% (Q4 2025), and 637.84% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 0.82% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | AbCellera Biologics | 1.55 Bn | 1.44 Bn | - | -519.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -519.12% |
| Dec 31, 2025 | -19.94% |
| Sep 30, 2025 | -637.84% |
| Jun 30, 2025 | -203.27% |
| Mar 31, 2025 | -1,077.24% |
| Dec 31, 2024 | -677.43% |
| Sep 30, 2024 | -785.42% |
| Jun 30, 2024 | -504.30% |
| Mar 31, 2024 | -407.98% |
| Dec 31, 2023 | -513.67% |
| Sep 30, 2023 | -433.55% |
| Jun 30, 2023 | -303.58% |
| Mar 31, 2023 | -328.99% |
| Dec 31, 2022 | -138.75% |
| Sep 30, 2022 | 26.26% |
| Jun 30, 2022 | -14.78% |
| Mar 31, 2022 | 53.25% |
| Dec 31, 2021 | 43.03% |
| Sep 30, 2021 | -388.16% |
| Jun 30, 2021 | -8.40% |